Carod-Artal FJ. Post-stroke depression (I). Epidemiology diagnostic criteria and risk factors. Revista de Neurologia. 2006;42:169–75.
Frasure-Smith N. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry. 2008;65:62–71.
Lesperance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation. 2002;105:1049–53.
Jonas BS, Franks P, Ingram DD. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Fam Med. 1997;6:43–9.
Davidson K, Jonas BS, Dixon KE, Markovitz JH. Do depression symptoms predict early hypertension incidence in young adults in the CARDIA study? Arch Intern Med. 2000;160:1495–500.
Jonas BS, Lando JF. Negative affect as a prospective risk factor for hypertension. Psychosom Med. 2000;62:188–96.
Markovitz JH, Matthews KA, Kannel WB, Cobb JL, Dagostino RB. Psychological Predictors of Hypertension in the Framingham-Study—is there tension in hypertension. Circulation. 1993;87:691.
Hildrum B, Mykletun A, Stordal E, Bjelland I, Dahl AA, Holmen J. Association of low blood pressure with anxiety and depression: the Nord-Trondelag Health Study. J Epidemiol Community Health. 2007;61:53–8.
Reiff M, Schwartz S, Northridge M. Relationship of depressive symptoms to hypertension in a household survey in Harlem. Psychosom Med. 2001;63:711–21.
Shinn EH, Poston WSC, Kimball KT, St Jeor ST, Foreyt JP. Blood pressure and symptoms of depression and anxiety: a prospective study. Am J Hypertens. 2001;14:660–71.
Wiehe M. Absence of association between depression and hypertension: results of a prospectively designed population-based study. J Hum Hypertens. 2006;20:434–9.
Hildrum B, Romild U, Holmen J. Anxiety and depression lowers blood pressure: 22-year follow-up of the population based HUNT study, Norway. BMC Public Health. 2011;11:601.
Patten SB. Propranolol and depression—evidence from the antihypertensive trials. Can J Psychiatry-Revue Canadienne de Psychiatrie. 1990;35:257–9.
Rathmann W, Haastert B, Roseman JM, Giani G. Cardiovascular drug prescriptions and risk of depression in diabetic patients. J Clin Epidemiol. 1999;52:1103–9.
Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:478–84.
Patten SB, Williams JVA, Love EJ. Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry-Revue Canadienne de Psychiatrie. 1996;41:469–76.
Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–7.
Huffman JC. Neuropsychiatric consequences of cardiovascular medications. Dialogues Clin Neurosci. 2007;9:29–45.
Dunn NR. Cohort study on calcium channel blockers, other cardiovascular agents, and the prevalence of depression. Br J Clin Pharmacol. 1999;48:230–3.
Kornischka J, Cordes J, Agelink MW. 40 years beta-adrenoceptor blockers in psychiatry. Fortschritte der Neurologie Psychiatrie. 2007;75:199–210.
Hollister LE. Calcium channel blockers in psychiatric disorders: a review of the literature. Can J Psychiatry. 1999;44:658–64.
Holmen J, Midthjell K, Kruger Ø, Langhammer A, Holmen TL, Bratberg GH, Vatten L, Lund-Larsen PG. The Nord-Trøndelag Health Study 1995–97 (HUNT 2): objectives, content, methods and participation. Norsk Epidemiologi. 2003;13:19–32.
Bjelland I, Dahl AA, Haug TT. The validity of the Hospital Anxiety and Depression Scale—an updated literature review. J Psychosom Res. 2002;52:69–77.
Bosworth HB. The association of psychosocial factors and depression with hypertension among older adults. Int J Geriatr Psychiatry. 2003;18:1142–8.
Wells KB, Golding JM, Burnam MA. Affective, substance use, and anxiety disorders in persons with arthritis, diabetes, heart-disease, high blood-pressure, or chronic lung conditions. Gen Hosp Psychiatry. 1989;11:320–7.
Gaynes BN, Burns BJ, Tweed DL, Erickson P. Depression and health-related quality of life. J Nerv Ment Dis. 2002;190:799–806.
Paterniti S, Alperovitch A, Ducimetiere P, Dealberto MJ, Lepine JP, Bisserbe JC. Anxiety but not depression is associated with elevated blood pressure in a community group of French elderly. Psychosom Med. 1999;61:77–83.
Jorgensen RS. Elevated blood pressure and personality: a meta-analytic review. Psychol Bull. 1996;120:293–320.
Panicker V, Evans J, Asvold BO, Dayan CM, Bjerkeset O. A paradoxial difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin Endocrinol. 2009;71:574–80.
Niu K. Home blood pressure is associated with depressive symptoms in an elderly population aged 70 years and over: a population-based, cross-sectional analysis. Hypertens Res. 2008;31:409–16.
Vasudev A, O’Brien JT, Tan MP, Parry SW, Thomas AJ. A study of orthostatic hypotension, heart rate variability and baroreflex sensitivity in late-life depression. J Affect Disord. 2011;131:374–8.
Oppenheim G. Propranolol-induced depression: mechanism and management. Aust N Z J Psychiatry. 1983;17:400–2.
Pollack MH. Comorbid anxiety and depression. J Clin Psychiatry. 2005;66:22–9.
Fitzgerald JD. Propranolol-induced depression. Br Med J. 1967;2:372–3.
Bright RA. Beta-blockers and depression. Evidence against an association. JAMA. 1992;267:1783–7.
Stoudemire A. Propranolol and depression: a reevaluation based on a pilot clinical trial. Psychiatric Med. 1984;2:211–8.
Carney RM. Prevalence of major depressive disorder in patients receiving beta-blocker therapy versus other medications. Am J Med. 1987;83:223–6.
Ried LD, McFarland BH, Johnson RE, Brody KK. Beta-blockers and depression: the more the murkier? Ann Pharmacother. 1998;32:699–708.
Gerstman BB, Jolson HM, Bauer M, Cho P, Livingston JM, Platt R. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol. 1996;49:809–15.
Schneier FR. Clinical practice. Social anxiety disorder. N Engl J Med. 2006;355:1029–36.
Zamorski MA. What to do when SSRIs fail: eight strategies for optimizing treatment of panic disorder. Am Fam Physician. 2002;66:1477–84.
Dannon PN. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol. 2000;10:165–9.
Ried LD. Depressive symptoms in coronary artery disease patients after hypertension treatment. Ann Pharmacother. 2006;40:597–604.
Keller SSFWW. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev. 2003;11:73–93.
Germain L. Treatment of recurrent unipolar major depression with captopril. Biol Psychiatry. 1988;23:637–41.
Hertzman M. Lisinopril may augment antidepressant response. J Clin Psychopharmacol. 2005;25:618–20.
Maas R. Antihypertensive therapy: special focus on drug interactions. Expert Opin Drug Saf. 2003;2:549–79.
Carter BL. Antihypertensive drug interactions. Drugs Today. 2005;41:55–63.
Carter BL, Lund BC, Chrischilles EA, Hayase N. Longitudinal analysis of antihypertensive drug interactions. Am J Hypertens. 2003;16:13A.
Roness A, Mykletun A, Dahl AA. Help-seeking behaviour in patients with anxiety disorder and depression. Acta Psychiatr Scand. 2005;111:51–8.
Simon G, Ormel J, VonKorff M, Barlow W. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry. 1995;152:352–7.
Roy-Byrne PP, Stang P, Wittchen HU, Ustun B, Walters EE, Kessler RC. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry. 2000;176:229–35.
Mykletun A, Bjerkeset O, Dewey M, Prince M, Overland S, Stewart R. Anxiety, depression, and cause-specific mortality: the HUNT study. Psychosom Med. 2007;69:323–31.
Herrmann C, Brand-Driehorst S, Buss U, Ruger U. Effects of anxiety and depression on 5-year mortality in 5, 057 patients referred for exercise testing. J Psychosom Res. 2000;48:455–62.